Rationale: Transplantation of allogeneic cardiac stem/progenitor cells (CPC) in experimental myocardial infarction promoted cardiac regeneration and improved heart function. Although this has enhanced prospects of using allogeneic CPC for cardiac repair, the mechanisms regulating the behavior of these allogeneic cells, which are central to clinical applications, remain poorly understood.
S
tem cell-based strategies to address the major cause of incurable heart failure, the myocyte deficiency, have raised hopes for novel therapeutic approaches. [1] [2] [3] [4] Transplantation of cardiac stem/progenitor cells 5 (CPC) into animal models of postmyocardial infarction (MI) heart failure attenuated left ventricular remodeling and improved ventricular function in the settings of acute and chronic MI. 6, 7 Currently, several different populations of CPC are being put forward as potential cell therapies to achieve cardiac repair/regeneration. 8 Clinical applications of autologous human CPC from the Stem Cell Infusion in Patients with Cardiomyopathy (SCIPIO) trial, which uses autologous c-kit-positive cells, and from the CardiosphereDerived Autologous Stem Cells to Reverse Ventricular Dysfunction (CADUCEUS) trial, which uses autologous cardiosphere-derived cells, provide evidence of feasibility and early hints of efficacy in a clinically meaningful setting. 2, 9 However, autologous approaches have their limitations, including a lack of therapeutic activity of CPC from the elderly and then typically disease-affected patient population, as well as logistical, economic, and time constraints. 10 Recent studies have shown in a rat MI model that transplantation of allogeneic cardiosphere-derived cells promotes cardiac regeneration and improves heart function. 11 Although the mechanisms that regulate the immunologic behavior of these allogeneic cells remain poorly understood, these studies provide a proof of concept for using allogeneic human CPC in clinical setting.
Whether immunologic behaviors of allogeneic CPC are linked to their therapeutic effects is unknown but is central to clinical application.
The allogeneic adaptive immune responses are orchestrated by T cells and are initiated against donor antigens presented by the molecules of major histocompatibility complex (human leukocytes antigens or HLA in humans) on stimulating cells or tissues. 12 This first activating signal to T cells is promoted by a second critical signal delivered by the interaction of B7 family costimulatory molecules, CD80/CD86, on stimulating cells with their binding partner CD28 on T cells, thus controlling alloantigen-specific T-cell proliferation and production of cytokine. 13 Other B7 members, including inducible costimulator ligand and programmed death ligand 1 (PD-L1), which is expressed in various types of cells, are also central regulators of T-cell-mediated immune responses. 13, 14 The allogeneic responses leading to graft rejection are predominantly mediated by CD4 + effector cells of the Th1 and Th2 proinflammatory phenotypes, [15] [16] [17] whereas CD4 + FoxP3 + regulatory T cells (Treg) limit alloimmunity. 18 Differentiation plasticity of proinflammatory Th1/Th2 and tolerogenic Treg subsets has been documented in murine models of transplantation. 19 Whether this equilibrium between Treg and proinflammatory Th1/Th2 subsets occurs in allogeneic CPC transplantation or it is skewed toward one direction is unknown.
Heart-derived progenitor cells are relative newcomers to regenerative cardiology, and understanding their immunologic behavior is critical for their establishment as candidate regenerative/reparative therapies. Therefore, in this study we investigated the mechanisms regulating the immunologic behavior of human c-kit-selected CPC (human CPC [hCPC] ) by analyzing the allogeneic T-cell response elicited by cryopreserved cells. We provide the first characterization of human allogeneic T-cell responses, in terms of proliferation and cytokine production, to allogeneic hCPC under physiological low-oxygen inflammatory conditions or not. We demonstrate the capacity of allogeneic hCPC to activate and expand Treg and to modulate ongoing immune responses. In addition, we demonstrate the involvement of the PD-L1/programmed cell death-1 (PD-1) pathway in the immunomodulatory capacities of these cells. Together, our data reveal that hCPC have a tolerogenic immune behavior controlled by PD-L1 molecule.
Methods

Cell Culture
Human CPC, referred to throughout the text as hCPC, were purified and expanded from 5 human myocardial samples by c-kit immunoselection as described, 20 fully characterized (Online Figures I-III) , and subsequently cryopreserved. After thawing, the cells were cultured as described under Detailed Methods in Online Data Supplement and grown at 37°C in a 3% O 2 atmosphere, thereby facilitating proper functioning and mimicking physio/pathological conditions. 21 Given their well-established immune behavior, 22 cryopreserved human bone marrow-derived mesenchymal stem cells (hMSC; Online Figure IV) , kindly provided by Dr J. Larghero (Cellular Therapy, Saint Louis Hospital, Paris, France), were cultured as described under Detailed Methods in Online Data Supplement and used as reference control cells. All experiments were performed with cells that had undergone no more than 8 passages and in 3% O 2 atmosphere. Peripheral blood mononuclear cells (PBMC) were prepared from the blood samples of 6 healthy donors and cryopreserved. The hCPC, hMSC, and PBMC from all the donors were genotyped for HLA using routine standard techniques at the Laboratory of Immunology and Histocompatibility, Saint Louis Hospital, Paris, France (Online Table I ).
Flow Cytometry
The expression of hCPC surface markers was analyzed by flow cytometry using specific antibodies (Online Table II ). Cells were acquired using the Canto II flow cytometer (BD Biosciences, le Pont-de-Claix, France) and analyzed using either the BD FACS Diva or the FlowJo software (Celeza, Olten, Switzerland). The expression of an antigen is presented as percentage of positive cells and as geometric mean of fluorescence intensity (MFI). Relative geometric MFI is calculated by dividing the geometric MFI of each test antibody by the geometric MFI of its isotype-matched control antibody as described.
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Western Blot
Proteins were separated from total cell extracts by SDS-PAGE and transferred to a nitrocellulose membrane (GE Healthcare Life Sciences, Aulnay-sous-Bois, France) and treated as described under Detailed Methods in Online Data Supplement.
Immunofluorescence Detection
The hCPC were grown on glass chamber slides (BD Biosciences). At subconfluence, the cells were fixed, permeabilized, neutralized, and then stained with appropriate antibodies as described under Detailed Methods in Online Data Supplement. Images were acquired by immunofluorescence microscopy using the Zeiss Axiovert 200M microscope at ×40 magnification and the Axiovision v4.5.0.0 software.
Allogeneic Immune Responses
Tailored mixed lymphocyte reactions to determine T-cell allogeneic immune responses were performed as previously described by us. 24 Briefly, responding carboxyfluorescein succinimidyl ester (CFSE)-labeled PBMC were cocultured with HLA-mismatched mitomycin C-treated stimulatory PBMC, hCPC, or hMSC. Staining with anti-CD3-PE-Cy7, anti-CD4-APC, anti-CD8-APC-H7, anti-CD25-PE, and 7-aminoactinomycin D (BD Biosciences) and flow cytometry were used to monitor the activation, proliferation, and cell death of different T-cell subsets. Treg were identified using anti-CD4-vioblue, anti-CD25-PE, anti-CD127-PE-Cy7, and anti-FoxP3-APC antibody staining, and their phenotypes were determined using anti-HLA-DR-PerCP, anti-PD-1(CD279)-fluorescein isothiocyanate, and anti-CD45RA-fluorescein isothiocyanate antibodies and flow cytometry. Regulatory CD4 +
CD25
high CD127 low/− T cells were sorted from PMBC using the anti-CD4-APC, anti-CD25-PE, and anti-CD127-PE-Cy7 antibodies and FACSAria cytometer. Sorted cells were then labeled + T cells and mitomycin C-treated hCPC, and then cocultured them with CFSElabeled autologous PBMC in the presence of PHA (1 µg/mL). The proliferation of autologous CFSE-labeled PBMC was evaluated by flow cytometry after 5 days of coculture. A division index was calculated using the FlowJo software.
Cytokine Assays
The levels of interferon-γ (IFNγ), IL-2, IL-10, and IL-4 in the supernatants of various cocultures were determined at the indicated time points by ELISA using specific kits (BD Biosciences) following the manufacturers' instructions.
RNA Silencing
To knockdown the surface expression of PD-L1, the hCPC were transiently transfected with 3 different PD-L1-specific stealth RNAi species ([1] CD274HSS120931, [2] CD274HSS120932, and [3] CD274HSS120933; Invitrogen Ltd, Paisley, UK) following standard procedures and as described under Detailed Methods in Online Data Supplement.
Statistical Analyses
Statistical analyses were performed using the GraphPad InStat3 software. Statistical significance (P values) was calculated using 1-way ANOVA, Student-Newman-Keuls multiple comparisons test. P<0.05 was considered statistically significant.
Results
Cellular Phenotype of Cryopreserved hCPC
hCPC were purified by c-kit immunoselection, as described, 20 from 5 different donors. Their phenotype, clonogenicity, genomic stability, capacity to form spheres and to differentiate to smooth muscle, endothelial cells, and cardiomyocytes, as well as their in vivo potency, were confirmed before cryopreservation (Online Figures I-III) . Further flow cytometry and immunostaining analyses of cryopreserved cells confirmed that these cells are negative for hematopoietic CD34 and CD45, and endothelial CD133 markers and display low levels of c-kit (2%-5%), but express SSEA-1, SSEA-4, CD90, CD73, CD105, and CD166 stem and progenitor markers ( Figure  1A ) and the cardiac lineage commitment factors Nkx2.5, GATA-4, Islet-1, and MEF2C ( Figure 1B ). These cells like the control hMSC also express the pluripotency transcription factors OCT4, SOX2, and NANOG, which were not detected in PBMC used as a negative control ( Figure 1C ). In contrast, the control hMSC do not express cardiac progenitor markers, such as GATA-4 and Islet-1 (Online Figure IVB) . In accordance, heat-map analysis shows that cardiac markers (FLK-1, TBX5) are expressed by these cardiac-derived progenitors but not by hMSC (Online Figure IC and ID) , indicating that they have a phenotype different from that of hMSC. They are also unlikely to be related to the recently described adult cardiacresident MSC-like stem cells (cardiac colony forming unitfibroblast). 25, 26 These cells, in contrast to the cardiac-derived progenitors under investigation, do not express the cardiac stem/progenitor markers Nkx2.5, GATA-4, MEF2C, or SOX2 and NANOG pluripotency factors. These results indicate that both the initially (Online Figure I ) and the cryopreserved investigated cells exhibit phenotypic traits typified by multiple types of previously reported human heart-derived stem/progenitor cell populations. 8, 27 Thus, they present a population of CPC with a mixed stem cell phenotype and will be referred to as hCPC throughout the text.
hCPC Display an Immune Phenotype Suitable for Allogeneic Applications
To determine the capacity of hCPC to induce an allogeneic immune response, we first characterized their expression of immune-relevant molecules, the major histocompatibility complex HLA class I and class II and costimulatory molecules. The hCPC from different donors (n=5) had similar immune phenotypes in that at baseline they expressed HLA class I, very low or negligible levels of HLA class II molecules, were negative for costimulatory molecules CD40, CD80, CD86, and inducible costimulator ligand (CD275), but expressed PD-L1 (CD274) (Figure 2A ). During inflammation, such as after myocardial injury, the presence of proinflammatory cytokines alters the phenotype and activity of various cell types. The cytokine IFNγ constitutes one of the most potent proinflammatory cytokines and upregulates/induces the expression of immune-relevant molecules. Treatment with IFNγ (100 U/mL) for 72 hours upregulated the expression of HLA class I and class II molecules, as well as of costimulatory PD-L1 molecule in hCPC as shown in Figure 2A by the percentage of positive cells and in Figure 2B by the relative geometric MFI (P≤0.01). However, IFNγ-treated hCPC (IFNγ-hCPC) did not show increased levels of the other costimulatory molecules (Figure 2A and 2B). Treatment with IFNγ did not induce noticeable morphological changes in hCPC ( Figure 2C , left) and did not modulate the expression levels of OCT4, SOX2, and NANOG ( Figure 2C , right) or of cell surface molecules, including adhesion molecules (Online Table III ). Together, these results indicate that the baseline immunophenotype of hCPC represents a weak immunogenic profile, which supports their clinical application in allogeneic settings. But their presence within an inflammatory environment, without modifying their progenitor phenotype, might enhance their immunogenic capacity given the potential expression of HLA molecules, which could facilitate their recognition by allogeneic T cells.
hCPC Elicit Weak Allogeneic T-Cell Response In Vitro
We then determined whether hCPC or IFNγ-hCPC could induce an allogeneic response using tailored 1-way mixed lymphocyte cultures. We investigated the responses of unfractionated PBMC from 6 HLA-mismatched healthy donors to the hCPC from 5 different donors. hMSC are low-immunogenic immunoregulatory cells that have been extensively studied 22 and, therefore, were used as reference control cells in our experiments. The hCPC from all the donors were able to elicit proliferation of CD4 + T cells (P<0.01 versus medium) but not CD8 + ( Figure 3A) . The hCPC-induced response was significantly lower than conventional allogeneic PBMC response (P<0.001) but comparable with that induced by hMSC ( Figure 3A) . Treatment of hCPC with IFNγ before coculturing with HLA-mismatched PBMC did not enhance their capacity to induce CD4 + or CD8 + T-cell proliferation ( Figure 3A) . Coculturing with higher titers of the hCPC did not enhance the allogeneic proliferative responses (data not shown), and annexin V/7-aminoactinomycin D staining and flow cytometry analysis indicated that the weak proliferation observed with hCPC was not because of a higher rate of PBMC death (Online Figure VA) . Similar CD4 + proliferation, but not CD8 + , was observed when purified HLA-mismatched CD3 + T cells were used as responders to hCPC and IFNγ-hCPC, but we did not observe significant proliferation in the presence of hMSC (Online Figure VB) .
In line with the low proliferative response, the levels of IFNγ in the supernatants of both hCPC and IFNγ-hCPC cocultures were weak and similar to those in the supernatants of T cells cultured in medium (P>0.05 versus medium; Figure 3B , left). However, low levels of IL-2 in the supernatants of both hCPC and IFNγ-hCPC cocultures were detected ( Figure 3B , right), and these levels are higher than those in the supernatants of T cells cultured with medium alone (P<0.001). No IL-4 was detected (data not shown), but substantial levels of IL-10 were found in hCPC cocultures (P<0.001 versus medium) and were higher when IFNγ-hCPC were used as stimulators (P<0.001 versus hCPC) ( Figure 3C , left). The IL-10 to IFNγ ratio was also significantly increased in both the hCPC and IFNγ-hCPC cocultures, compared with medium alone or with the allogeneic PBMC (P<0.001; Figure 3C , right). Of note, neither the hCPC nor the IFNγ-hCPC produced any of the tested cytokines (Online Figure VC) . The supernatants of the control hMSC cocultures showed significant levels of IFNγ and IL-2 compared with medium (P<0.001), but lower than conventional allogeneic PBMC response (P<0.001; Figure 3B ). Both the IL-10 and IL-10 to IFNγ ratio in the presence of hMSC were lower than those observed with hCPC (P<0.001) and similar to that in the medium or within conventional allogeneic response ( Figure  3C ). Thus, although comparable with the control hMSC-induced response (cell proliferation), the hCPC-induced T-cell response in allogeneic settings has its particularities. hCPC do not induce a substantial Th1 (IFNγ production) or Th2 (IL-4 production) response but rather elicit the proliferation of a specific subpopulation of IL-10-producing CD4 + T cells.
hCPC Have an Immunomodulatory Capacity
Then we investigated the capacities of hCPC to modulate an ongoing immune response in an allogeneic setting. HLAmismatched PBMC were stimulated with the polyclonal activator of T-cell PHA in the absence or presence of mitomycin C-treated hCPC, IFNγ-hCPC, or control hMSC. The presence of hCPC or IFNγ-hCPC efficiently downmodulated the PHA-induced proliferation of both CD4 + and CD8 + T cells. The division index of the PHA-activated CD4 + and CD8 + T cells decreased by ≈75% ( Figure 4A, top) , whereas the percentage of proliferating cells decreased by ≈50% (P<0.001 versus medium; Figure  4A , bottom). Coculturing hCPC or IFNγ-hCPC in transwell settings almost completely blocked their inhibitory effect on PHA-induced CD4 + and CD8 + T-cell proliferation (P<0.001), indicating that these cells exert their modulatory effects mainly through cell-cell contact ( Figure 4A ). hMSC also decreased PHA-induced proliferation of both CD4 + and CD8 + T cells by ≈65% (P<0.001 versus medium). But when cultured in transwell settings, inhibition of proliferation was only partially affected ( Figure 4A, bottom) , which is in line with previous studies demonstrating that hMSC immunomodulatory function requires soluble factors with limited diffusion distance. 22, 29 The presence of hCPC, similar to hMSC, also downregulated the production of IFNγ and IL-2 by PHA-activated T cells by 80% to 85% (P<0.001 versus medium; Figure 4B ). However, both hCPC and hMSC upregulated the production of IL-10 and increased the IL-10 to IFNγ ratios (P<0.001 versus medium; Figure 4C ). Interestingly, IFNγ-hCPC were more efficient than untreated hCPC in downregulating the production of IL-2 (P<0.01) and in increasing IL-10 production and IL-10 to IFNγ ratios (P<0.001). Taken together, our results indicate that hCPC are endowed with immunoregulatory function(s), which is likely to be maintained in an inflammatory environment, as IFNγ-hCPC were also efficient suppressors of an ongoing immune response.
hCPC Activate Treg in Allogeneic Settings
hCPC in allogeneic settings induce the proliferation of a CD4 + T-cell subpopulation and downmodulate an ongoing immune response in a cell-cell contact manner. Therefore, we investigated whether this subpopulation has a regulatory/ suppressive capacity and could be implicated in the hCPC immunomodulatory effect. HLA-mismatched CD4 + T cells were cultured alone or cocultured with mitomycin C-treated hCPC, IFNγ-hCPC, or control hMSC, and the phenotype of proliferating cells was determined. Coculturing with hCPC or IFNγ-hCPC induced the proliferation of a CD4 + T-cell subset that express high levels of CD25 and FoxP3 but low levels of CD127, which is indicative of a T-regulatory phenotype ( Figure  5A , top). Quantification analysis indicates that hCPC and IFNγ-hCPC induce almost a 6-fold increase in the percentage of CD4
high cells ( Figure 5A , left histogram; P<0.001 versus medium). In addition, at least 80% of these cells were proliferative as determined by CFSE labeling compared with only 20% of cells in control conditions (medium; P<0.001; Figure 5A , right histogram). As a reference control, we found that hMSC have the same capacity as hCPC in inducing this Treg phenotypic cell population ( Figure 5A ).
We also checked for the expansion of these cells in cocultures of PHA-stimulated HLA-mismatched PBMC and mitomycin C-treated hCPC, treated or not with IFNγ. Interestingly, we observed a significant increase in the number of CD4
high T cells in the presence of hCPC or IFNγ-hCPC, compared with PHA stimulation alone, and this was dependent on the PBMC to hCPC ratio ( Figure  5B ), which strongly supports their implication in hCPC-induced immunomodulation.
Then, we investigated the capacity of the T-cell subset activated by hCPC in allogeneic settings to suppress T-cell activation. low/− T cells (P<0.001; Figure 5C ). These results indicate that the subpopulation of CD4 + T cells that is activated by hCPC in our allogeneic model system has the phenotypic and functional characteristics of suppressive Treg.
Characterization of hCPC-Activated Treg
We then focused on characterizing the hCPC-activated CD4 + CD25 high CD127 low/− FoxP3 high Treg. We found that ≈90% of these cells are HLA-DR-positive, whereas ≈77% were found to be CD45RA-negative ( Figure 6A ). hCPC express the costimulatory molecule PD-L1. We, therefore, examined whether hCPC-induced CD4 low/− Treg have an activated (expression of HLA-DR and PD-1) effector (loss of CD45RA) phenotype according to that described by Sakaguchi et al. 18 These cells have been described as potent downmodulators of the immune and inflammatory responses in normal and pathological context, as well as in allogeneic transplantation. 18 We then confirmed the capacity of the hCPC to activate and expand effector allogeneic Treg. We sorted CD4
low/− Treg 18 from HLA-mismatched PBMC, verified that they express FoxP3, and then cocultured them with hCPC for 7 days. As depicted in Figure 6B low− T cells (P<0.001), demonstrating that the suppressive capacity of these cells occurs mainly through cell-cell contacts ( Figure 6C ).
PD-L1/PD-1 Orchestrates the Immunologic Properties of hCPC
We found that hCPC preferentially activate the CD4 Figure 6A ). In addition, hCPC express PD-L1 (Figure 2 ), and we showed that hCPC-induced immune regulation is mainly through cell-cell contacts ( Figure 4A ). Therefore, we looked at the possible involvement of the PD-L1/PD-1 system in the immunoregulatory behavior of hCPC. We first investigated the formation and proliferation of the CD4
high Treg subset on stimulation of HLA-mismatched PBMC by hCPC and IFNγ-hCPC in the presence or absence of a blocking anti-PD-L1 antibody, known to disrupt the PD-L1/PD-1 interactions. 31 As depicted in Figure 7A , the presence of the blocking anti-PD-L1, but not its isotype control, almost completely abolished the formation and proliferation of CD4 
FoxP3
high T cells were observed in the presence of anti-PD-L1 versus 4.5% in the isotype control (P<0.001), and none of these cells were proliferating (P<0.001). We also examined the effect of the blocking anti-PD-L1 antibody on the capacities of the hCPC to induce the proliferation and expansion of freshly isolated CD4
low/− Treg. The presence of the blocking anti-PD-L1 antibody, but not its isotype control, also substantially abolished the capacities of the hCPC to expand and activate HLA-mismatched purified Treg ( Figure 7B, top) . The percentage of proliferating cells decreased by ≈69%, and only 4% to 5% of these proliferating cells were HLA-DR-positive (activated/effector) in the presence of anti-PD-L1. Then we examined the effect of blocking anti-PD-L1 on hCPC-mediated immune modulation. We found that PHA-induced proliferation of CD4 + and CD8 + T cells was restored by 76% and 92%, respectively, in the presence of the blocking anti-PD-L1 but not its isotype control (P<0.001; Figure 7C ).
We then knocked down PD-L1 in the hCPC by RNA interference and tested the capacity of these cells to downregulate PHA-induced T-cell activation. Transfection of hCPC with 3 different PD-L1-specific small interfering RNA (siRNA) sequences (siRNA 1, 2, and 3) remarkably reduced the cell surface expression of PD-L1 (average reduction of 85%), whereas transfection with 2 different control siRNA had no effect ( Figure 8A ). The presence of allogeneic hCPC and control siRNA-transfected hCPC decreased the division index of HLA-mismatched PHA-stimulated T cells by 66% and 51%, respectively, but PD-L1 siRNA-transfected cells + and CD8 + observed in the presence of allogeneic hCPC or control siRNA-transfected cells was also almost completely abrogated by the presence of PD-L1 siRNA-transfected cells (P<0.01; Figure 8C ). Furthermore, we found that the level of IL-10 detected in the PD-L1 siRNA-transfected hCPC cocultures was significantly decreased compared with that detected in the allogeneic hCPC or control siRNA-transfected cocultures (P<0.01; Figure 8D ). This suggests that the PD-L1/PD-1 system is implicated in the production of IL-10 that we detected in all the hCPC/HLA-mismatched PBMC cocultures. Our results indicate that in allogeneic settings, PD-L1 is involved in both the capacities of hCPC to activate and expand effector Treg and in their capacity to downregulate an ongoing immune response.
Discussion
Preclinical experiments with allogeneic cardiosphere-derived cells 11 have opened up a new treatment paradigm and have made the use of allogeneic hCPC via cell banks a more realistic proposition, assuming that cryopreserved cells retain their original characteristics and are immunologically safe. In the present study, we provide the first detailed description of T-cell responses to cryopreserved allogeneic hCPC. We show that cryopreserved hCPC retain their primitive pluripotent and early cardiac lineage-committed phenotype. Tailored immune assays showed that these cells are hypoimmunogenic because, whether under inflammatory conditions or not, they lack the costimulatory molecules CD80/ CD86 required for conventional Th1 or Th2 type T-cell responses. In contrast, the hCPC express the costimulatory molecule PD-L1, which endows them with the capacity to Patients who experience heart failure after MI have reduced numbers of circulating Treg. 32 We demonstrate that under conditions mimicking the physio/pathological environment of the injured myocardium, allogeneic hCPC mainly activate and expand Treg rather than proinflammatory Th1 cells, which are typically activated in allogeneic reactions. Recent studies have attributed a critical role to Treg in cardiac repair after MI. Insufficient recruitment of Treg worsens ventricular remodeling, 33 whereas adoptive transfer of Treg in a rat model of MI prevents adverse cardiac remodeling at the infarcted site, reduces macrophage and T-cell infiltration to the site, and protects the resident cardiomyocytes against apoptosis. 34 Our results strongly suggest that the administration of allogeneic hCPC would, through activation and expansion of Treg, provide similar protective/reparative effects. The mechanisms by which stem cells promote cardiac repair are not yet fully understood. Initially, it was established that the transplanted cells differentiate into cardiac cells and blood vessels and replace damaged cells. Growing evidence also indicated that stem cells, including hMSC and hCPC, perform the following: (1) release growth factors and molecules that promote angiogenesis; (2) attenuate the postinfarct adverse remodeling; (3) reduce myocardial apoptosis; and (4) stimulate resident CPC to repair damage. Collectively, this can be summarized as the paracrine effect. Although animal studies clearly indicated that the engraftment and differentiation specify the regenerative mechanism, 35, 36 the paracrine effect is today also recognized as part of the overall regenerative process. 2, [37] [38] [39] [40] [41] [42] In this context, our present study underscores the capacity of allogeneic hCPC to elicit Treg response as an indirect paracrine effect that would promote cardiac repair and suggests that the presumed functional benefit of allogeneic CPC could be also linked to their inherent immune properties. This notion is reinforced by our results showing that in allogeneic settings hCPC can inhibit an ongoing inflammatory T-cell response. This is the first demonstration of the immunomodulatory capacity of hCPC in vitro. Our results indicate that hCPC can downregulate a T-cell response elicited by mismatched major histocompatibility complex molecules in inflammatory conditions, which mimics the post-MI inflammatory response. Indeed, maintaining the hCPC in the presence of the proinflammatory cytokine IFNγ does not alter the immunomodulatory capacity of hCPC or favor activation of a Th1 type response over a regulatory immune response. These data suggest that even after their introduction into an inflammatory environment, the hCPC would still have the same or better immunomodulatory potential. Thus, transplantation of allogeneic hCPC would not aggravate MI inflammation but would rather participate in its resolution. This is likely because of the fact that IFNγ, although it considerably upregulated HLA class II molecules on hCPC promoting the first T-cell activation signals, did not induce the promoters of conventional Th1 or Th2 responses, CD80/CD86, but rather increased the expression of immune regulator PD-L1 costimulatory molecule.
Allogeneic effector T-cell responses are susceptible to PD-1 pathway modulation as evidenced in models of graft-versus-host disease 43 and allogeneic organ transplantation. 44 We showed that hCPC in allogeneic settings activate and expand functional Treg, and the presence of anti-PD-L1 blocking antibody or PD-L1 knockdown almost completely abolishes hCPC-induced activation and proliferation of Treg and the immunomodulatory actions of the hCPC. Our data do not dismiss that soluble factors in conjunction with cell-cell contact could be implicated in hCPC immunomodulatory capacity. In hMSC immunomodulation, a role for the soluble HLA-G5 in a cell contact-dependent manner, for example, has been identified. 22, 45 Similar scenarios might occur with hCPC. Reverse signaling through PD-L1 interaction with PD-1 delivers signals to PD-L1-expressing cells, 14 which might upregulate the production or release of soluble factor(s) by hCPC, contributing to the suppression of allogeneic T-cell proliferation. Signaling through PD-L1 in hCPC is not known, and future studies will investigate this possibility.
Our results assign a critical role to PD-L1 in orchestrating the immune behavior of hCPC. PD-L1 is expressed constitutively on both hematopoietic (resting T cells, B cells, dendritic cells, macrophages, and Treg) and nonhematopoietic cells (parenchymal and endothelial cells). 30 Resting T cells express low levels of PD-1 receptor, the expression of which is inducible on CD4 + and CD8 + T cells, natural killer cells, activated monocytes, and B cells. 30 We found that hCPC constitutively express a substantial level of PD-L1, and hCPC-induced allogeneic Treg express substantial amounts of PD-1. This pathway has been shown to regulate T-cell responses and inflammation in various disease settings, including atherosclerosis, 46 allograft vascular disease, 47 and, more recently, myocarditis. 48 PD-L1 regulates the development, maintenance, and function of Treg. 49 Murine PD-L1 −/− antigen-presenting cells are profoundly defective in terms of the conversion of CD4 + CD62L high Foxp3 T cells to regulatory cells, and PD-L1 alone is sufficient to induce the conversion of naive T cells to functional Foxp3 high Treg. 49 The constitutive expression of PD-L1 endows the hCPC with a dominant pathway that in allogeneic settings polarizes CD4 + T cells toward a Treg phenotype.
We did not investigate the mechanisms by which PD-L1 on hCPC regulates the development of allogeneic Treg. However, previous studies have shown the implication of PD-L1/PD-1 axis in converting effector CD4 + Th1 cells into Treg. PD-1 activation and subsequent activation of SHP1/SHP2 signaling on binding of PD-L1 induce Th1 cell plasticity by reducing STAT1 activation, which is critical for maintaining Th1 phenotype. 19 The PD-L1/PD-1 pathway can also flip the molecular switch in a naive CD4 + T cell toward Treg development by inhibiting the Akt/mTOR signaling cascade, probably through the upregulation of the phosphoinositide 3-kinase signaling antagonist phosphatase and tensin homolog. 49 PD-L1 also promotes and maintains the induced Treg by sustaining and enhancing Foxp3 expression. 49 In our model, similar scenarios could be implicated in the development of allogeneic Treg by hCPC, although this warrants further investigation.
The PD-L1/PD-1 interaction delivers cosignals to T cells, thereby promoting their proliferation and secretion of IL-10, notably when the antigen-presenting cells lack expression of CD80/CD86 and the CD28 cosignaling pathway is not operating. 50 We demonstrated the following: (1) hCPC express neither CD80 nor CD86; (2) hCPC activate a Treg response (IL-10) rather than a Th1 (IFNγ) or Th2 (IL-4) type response in a PD-L1-dependent manner; (3) hCPC immunomodulate the PHA-induced response in a manner that is dependent on their activation of regulatory cells and PD-L1; (4) IFNγ-hCPC compared with hCPC induce higher production of IL-10 and have higher expression of PD-L1; and (5) knocking down PD-L1 significantly decreases the secretion of IL-10 in immunomodulation assays. Taken together, these findings suggest that IL-10 in our allogeneic model system is related to PD-L1/PD-1 cosignaling to T cells. Interestingly, a similar correlation might also exist in the allogeneic hMSC model. hMSC do not constitutively express PD-L1, but we found that the significant production of IL-10 in hMSC/PHA-activated HLA-mismatched PBMC cocultures coincides with the significant upregulation of PD-L1 expression on hMSC (Online Figure VI) . IL-10 has been implicated in the regulation of the postinfarction inflammatory response. 51 Although the results from loss-of-function studies in mouse models have been somewhat contradictory, 52 ,53 administration of exogenous IL-10 significantly reduces inflammation, improves cardiac function, and attenuates ventricular remodeling after MI in mice. 54 The role of the PD-L1/ PD-1 pathway in promoting transplantation tolerance has been demonstrated in various murine models of transplantation, notably heart allografts. 30 Given its implication in IL-10 secretion and Treg generation after an interaction between T cells and allogeneic hCPC, we suggest a previously undemonstrated role in cardiac cell therapy for the PD-L1/PD-1 pathway, that is, in promoting the hCPC paracrine effect. This idea draws together current evidence indicating a pivotal role for PD-L1/PD-1 in controlling and managing allogeneic but also xenogeneic reactions via Treg-dependent and T-cell-independent mechanisms 19, 55, 56 and the critical role of myocardial PD-L1/PD-1 in the control of immune-mediated cardiac injury. 48, 57 The balance between the positive (activating Th1 inflammatory response) and negative (activating regulatory response) signals that an antigen-presenting cell delivers to a T cell on encounter determines the outcome of the alloimmune response. Regardless of the underlying mechanisms, the present work demonstrates that the inherent immune features of hCPC shift their signaling capacities within the allogeneic setting toward delivery of signals that promote the development, maintenance, and functioning of an anti-inflammatory immunoregulatory response. This is critical to decrease allogeneic rejection risk and to allow the persistence of repair cells so as to favor cardiac repair/regeneration. Our work with hCPC emphasizes the paradigm proposed by the Marban group of using allogeneic human cardiac repair cells from cell banks as off-the-shelf products for cellular cardiac repair 11 and provides the first evidence for a potential allogeneic-driven benefit of human CPC. The herein demonstrated PD-L1-dependent allogeneic-driven immunomodulatory capacity of hCPC promotes their clinical translation and paves the way for using the expression of PD-L1 as a biomarker to identify and select lowrisk, high-benefit allogeneic cardiac repair cells.
